AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15086643 — intervention group
Group type: EXPERIMENTAL
Intervention: Agility training
Number of subjects: 98
Study 15086643 — intervention group
Group type: COMPARATOR
Intervention: Stretching (sham) exercises
Number of subjects: 98
Study 11719727 — intervention group
Group type: COMPARATOR
Intervention: Fluvoxamine at 0 mg/d
Number of subjects: 9
Study 11719727 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine at 25 mg/d
Number of subjects: 9
Study 11719727 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine at 75 mg/d
Number of subjects: 9
Study 9222234 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous foscarnet
Number of subjects: 316
Study 9222234 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ganciclovir
Number of subjects: 316
Study 9063814 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR-RFLP assay with a mismatched primer for ALDH2 genotyping
Number of subjects: 0
Study 9063814 — intervention group
Group type: EXPERIMENTAL
Intervention: Nested PCR for ADH2 genotyping
Number of subjects: 0
Study 9063814 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly designed primer pair for ADH2 sequence amplification
Number of subjects: 0
Study 9063814 — intervention group
Group type: EXPERIMENTAL
Intervention: RFLP and SSCP analyses of PCR products with the new primer set
Number of subjects: 0
Study 9063814 — intervention group
Group type: EXPERIMENTAL
Intervention: ADH2 and ALDH2 allele frequencies
Number of subjects: 0
Study 3294978 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 30 mg/day for 4 weeks
Number of subjects: 14
Study 3294978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 29696220 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated motivational interviewing (MI) and multi-modal exercise intervention (12 weeks, 3 times per week for 1 hour)
Number of subjects: 68
Study 29696220 — intervention group
Group type: COMPARATOR
Intervention: Delayed control group (received the same intervention 12 weeks later)
Number of subjects: 68
Study 26850076 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibutilide (0.25 mg intravenous)
Number of subjects: 200
Study 26850076 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 200
Study 26850076 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibutilide
Number of subjects: 200
Study 24142988 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise programme (daily stretching exercise and twice-a-week muscle endurance training)
Number of subjects: 567
Study 24142988 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 567
Study 24142988 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise programme
Number of subjects: 567
Study 24142988 — intervention group
Group type: COMPARATOR
Intervention: Exercise programme and Control group
Number of subjects: 567
Study 21826536 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Foundations (FF) program
Number of subjects: 0
Study 19914702 — intervention group
Group type: EXPERIMENTAL
Intervention: fesoterodine 4 mg
Number of subjects: 358
Study 19914702 — intervention group
Group type: EXPERIMENTAL
Intervention: fesoterodine 8 mg
Number of subjects: 358
Study 19914702 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 358
Study 18375074 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 I.U.)
Number of subjects: 10
Study 16100213 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept, 25 mg subcutaneously twice a week
Number of subjects: 18
Study 16100213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 16100213 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 18
Study 12019049 — intervention group
Group type: EXPERIMENTAL
Intervention: S-adenosylmethionine (SAMe)
Number of subjects: 11
Study 11501126 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH (0.2 U.kg‐1 subcutaneously at 8 a.m. each morning for 14 days)
Number of subjects: 42
Study 11501126 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH
Number of subjects: 42
Study 11501126 — intervention group
Group type: COMPARATOR
Intervention: Control (normal saline as placebo)
Number of subjects: 42
Study 9012305 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway
Number of subjects: 100
Study 1579399 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular diphtheria‐tetanus toxoids‐pertussis (DTP (ADTP))
Number of subjects: 380
Study 1579399 — intervention group
Group type: COMPARATOR
Intervention: Whole‐cell DTP (WDTP)
Number of subjects: 380
Study 4096057 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily training programme during hospital stay
Number of subjects: 27
Study 4096057 — intervention group
Group type: COMPARATOR
Intervention: Conventional rest in bed (Control)
Number of subjects: 27
Study 31377342 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Immunotherapy (OIT)
Number of subjects: 30
Study 31377342 — intervention group
Group type: COMPARATOR
Intervention: Postavoidance SU plasma
Number of subjects: 30
Study 29475784 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 4512
Study 24481541 — intervention group
Group type: EXPERIMENTAL
Intervention: MHTS service intervention package
Number of subjects: 2238
Study 23190552 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based care pathway interventions for COPD exacerbation; 38 key interventions developed.
Number of subjects: 0
Study 23190552 — intervention group
Group type: EXPERIMENTAL
Intervention: Process and outcome indicators; 24 process indicators and 15 outcome indicators developed.
Number of subjects: 0
Study 21149772 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy (cryopexy)
Number of subjects: 86
Study 21149772 — intervention group
Group type: COMPARATOR
Intervention: Laser photocoagulation (laserpexy)
Number of subjects: 86
Study 16997421 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 214
Study 16997421 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 214
Study 15855978 — intervention group
Group type: EXPERIMENTAL
Intervention: Wireless capsule endoscopy
Number of subjects: 24
Study 15855978 — intervention group
Group type: COMPARATOR
Intervention: Barium contrast series
Number of subjects: 24
Study 15855978 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 24
Study 12477214 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual treatment plus a patient education program (Group B)
Number of subjects: 77
Study 12477214 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment (Group A)
Number of subjects: 77
Study 12477214 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual treatment plus a patient education program (Group B) in moderate-to-severe asthma
Number of subjects: 77
Study 9658727 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cyclophosphamide (1.5 g/m2 i.v. day 0) plus G-CSF (5 ug/kg/day s.c. from day +1 to end of leukapheresis)
Number of subjects: 28
Study 9658727 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cyclophosphamide plus G-CSF
Number of subjects: 28
Study 8294680 — intervention group
Group type: COMPARATOR
Intervention: Biphasic defibrillation alone
Number of subjects: 13
Study 8294680 — intervention group
Group type: COMPARATOR
Intervention: Sequential defibrillation alone
Number of subjects: 13
Study 8294680 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined biphasic plus sequential defibrillation
Number of subjects: 13
Study 8294680 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined waveform
Number of subjects: 13
Study 2962947 — intervention group
Group type: EXPERIMENTAL
Intervention: Yeast-derived hepatitis B vaccines (partially purified or highly purified)
Number of subjects: 50
Study 2962947 — intervention group
Group type: COMPARATOR
Intervention: Plasma-derived hepatitis B vaccine (control)
Number of subjects: 50
Study 31935168 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioceramic (BC) group wearing compressive socks made of fabrics with embedded ceramic powder for 8 hours a day for 28 days
Number of subjects: 30
Study 31935168 — intervention group
Group type: COMPARATOR
Intervention: Placebo group wearing compressive socks of the same material without ceramic powder
Number of subjects: 30
Study 31935168 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioceramic (BC) group
Number of subjects: 30
Study 31935168 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 30
Study 30089607 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-assisted Internet-Based Cognitive Behavioral Therapy (iCBT)
Number of subjects: 179
Study 30089607 — intervention group
Group type: COMPARATOR
Intervention: Therapist-assisted Internet-Based Standard Progressive Relaxation Training (iPRT)
Number of subjects: 179
Study 28162905 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral arm training (30 minutes, additional to general occupational therapy)
Number of subjects: 30
Study 28162905 — intervention group
Group type: COMPARATOR
Intervention: General occupational therapy (30 minutes)
Number of subjects: 30
Study 26591678 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 120
Study 26591678 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium (medication group)
Number of subjects: 120
Study 23413266 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 126
Study 23413266 — intervention group
Group type: COMPARATOR
Intervention: Mandibular Advancement Device (MAD)
Number of subjects: 126
Study 23413266 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 126
Study 21540753 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise training (EX) - concurrent circuit resistance exercise (RE) followed by endurance exercise (EE) at 60% of predicted maximal heart rate, 3 days per week
Number of subjects: 24
Study 21540753 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise training (EX)
Number of subjects: 24
Study 21540753 — intervention group
Group type: COMPARATOR
Intervention: No exercise control
Number of subjects: 24
Study 18344729 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine 300 mg/d
Number of subjects: 34
Study 18344729 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 16858462 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving therapy
Number of subjects: 66
Study 16858462 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Problem-Solving Inventory‐Revised
Number of subjects: 66
Study 16858462 — intervention group
Group type: EXPERIMENTAL
Intervention: Profile of Mood States
Number of subjects: 66
Study 14533211 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 hourly change of closed suction catheter (CSC)
Number of subjects: 158
Study 14533211 — intervention group
Group type: COMPARATOR
Intervention: 48 hourly change of closed suction catheter (CSC)
Number of subjects: 158
Study 10761291 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary and secondary PPV without autologous thrombocyte concentrate (ATC)
Number of subjects: 75
Study 10761291 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary and secondary PPV with early increase of IOP
Number of subjects: 75
Study 10761291 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-group B1 (maximum postoperative IOP deviation between 25-35 mm Hg)
Number of subjects: 75
Study 10761291 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-group B2 (maximum postoperative IOP deviation above 35 mm Hg)
Number of subjects: 75
Study 10761291 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration of ATC during PPV
Number of subjects: 75
Study 8973986 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors
Number of subjects: 0
Study 8973986 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 0
Study 1606213 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 hour educational package + 1 hour group discussion intervention (75% of subjects)
Number of subjects: 118
Study 1606213 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of a person with AIDS (PWA) during group discussion (in person or on video)
Number of subjects: 118
Study 3709614 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 2 mg (single and multiple doses)
Number of subjects: 12
Study 3709614 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 0.5 mg (single dose)
Number of subjects: 12
Study 3709614 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs (single and multiple doses)
Number of subjects: 12
Study 30878630 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose tigecycline (100 mg q12h)
Number of subjects: 105
Study 30878630 — intervention group
Group type: COMPARATOR
Intervention: Standard dose tigecycline (50 mg q12h)
Number of subjects: 105
Study 30878630 — intervention group
Group type: EXPERIMENTAL
Intervention: Cured group
Number of subjects: 105
Study 30878630 — intervention group
Group type: COMPARATOR
Intervention: Failure group
Number of subjects: 105
Study 30878630 — intervention group
Group type: EXPERIMENTAL
Intervention: AUIC
Number of subjects: 105
Study 30878630 — intervention group
Group type: EXPERIMENTAL
Intervention: MIC
Number of subjects: 105
Study 29481447 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy with 30 J
Number of subjects: 15
Study 29481447 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy with 15 J
Number of subjects: 15
Study 29481447 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy with 60 J
Number of subjects: 15
Study 29481447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 27134061 — intervention group
Group type: EXPERIMENTAL
Intervention: Branched-chain amino acids (tryptophan, tyrosine, phenylalanine)
Number of subjects: 111
Study 24708507 — intervention group
Group type: EXPERIMENTAL
Intervention: Crying sound during separation phase
Number of subjects: 0
Study 24708507 — intervention group
Group type: COMPARATOR
Intervention: Laughing sound during separation phase
Number of subjects: 0
Study 24708507 — intervention group
Group type: EXPERIMENTAL
Intervention: Crying sound during response phase
Number of subjects: 0
Study 24708507 — intervention group
Group type: COMPARATOR
Intervention: Laughing sound during response phase
Number of subjects: 0
Study 22178762 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy plus a psychoeducational group intervention on alcohol drinking related to stress and trauma (PAST)
Number of subjects: 66
Study 22178762 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 66
Study 20647198 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m²/week for 4 weeks)
Number of subjects: 44
Study 20647198 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cyclophosphamide for 3 to 6 months followed by azathioprine
Number of subjects: 44
Study 20647198 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 44
Study 20647198 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cyclophosphamide
Number of subjects: 44
Study 18572030 — intervention group
Group type: EXPERIMENTAL
Intervention: Cypher Select stent (n = 48)
Number of subjects: 95
Study 18572030 — intervention group
Group type: COMPARATOR
Intervention: Taxus Express-2 stent (n = 47)
Number of subjects: 95
Study 18572030 — intervention group
Group type: EXPERIMENTAL
Intervention: Cypher Select stent (n = 40)
Number of subjects: 95
Study 18572030 — intervention group
Group type: COMPARATOR
Intervention: Taxus Express-2 stent (n = 38)
Number of subjects: 95
Study 18572030 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment
Number of subjects: 95
Study 18572030 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent type
Number of subjects: 95
Study 15765953 — intervention group
Group type: EXPERIMENTAL
Intervention: Super‐Torque Lux 3 650B (KaVo, Biberach, Germany)
Number of subjects: 20
Study 15765953 — intervention group
Group type: EXPERIMENTAL
Intervention: BORA 898LE (BienAir SA, Bienne, Switzerland)
Number of subjects: 20
Study 15765953 — intervention group
Group type: EXPERIMENTAL
Intervention: Toplight (W&H Dentalwerk, Burmoos, Austria)
Number of subjects: 20
Study 12061197 — intervention group
Group type: EXPERIMENTAL
Intervention: Icodextrin-based dialysis solution
Number of subjects: 18
Study 12061197 — intervention group
Group type: COMPARATOR
Intervention: Glucose-based dialysis solution
Number of subjects: 18
Study 10363074 — intervention group
Group type: EXPERIMENTAL
Intervention: ketorolac 10 mg p.o. (t.i.d.)
Number of subjects: 138
Study 10363074 — intervention group
Group type: COMPARATOR
Intervention: diclofenac 50 mg p.o. (t.i.d.)
Number of subjects: 138
Study 10363074 — intervention group
Group type: EXPERIMENTAL
Intervention: ketorolac
Number of subjects: 138
Study 10363074 — intervention group
Group type: COMPARATOR
Intervention: diclofenac
Number of subjects: 138
Study 8650509 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually based physiotherapy
Number of subjects: 33
Study 8650509 — intervention group
Group type: EXPERIMENTAL
Intervention: Group exercise
Number of subjects: 33
Study 8650509 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 33
Study 2202655 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% idoxuridine cream
Number of subjects: 50
Study 2202655 — intervention group
Group type: COMPARATOR
Intervention: 0.25% idoxuridine cream
Number of subjects: 50
Study 7428566 — intervention group
Group type: EXPERIMENTAL
Intervention: labetalol
Number of subjects: 26
Study 7428566 — intervention group
Group type: COMPARATOR
Intervention: Aldomet
Number of subjects: 26
Study 31925601 — intervention group
Group type: EXPERIMENTAL
Intervention: adapted parent‐child interaction therapy intervention with foster‐parent child dyads
Number of subjects: 0
Study 31925601 — intervention group
Group type: EXPERIMENTAL
Intervention: multiple evidence-based treatments (EBTs)
Number of subjects: 0
Study 29955828 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline adherence (≥80%)
Number of subjects: 207
Study 29955828 — intervention group
Group type: COMPARATOR
Intervention: Varenicline adherence (not adherent)
Number of subjects: 207
Study 29955828 — intervention group
Group type: EXPERIMENTAL
Intervention: Early reductions in depressed mood and satisfaction from smoking
Number of subjects: 207
Study 29955828 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater adherence
Number of subjects: 207
Study 28086857 — intervention group
Group type: EXPERIMENTAL
Intervention: Social behaviour change communication (SBCC) strategy involving a radio drama and community mobilization
Number of subjects: 1440
Study 28086857 — intervention group
Group type: COMPARATOR
Intervention: Radio programming alone
Number of subjects: 1440
Study 25909422 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepilex Ag dressing applied every 5 to 7 days (n = 71)
Number of subjects: 153
Study 25909422 — intervention group
Group type: COMPARATOR
Intervention: Silver sulfadiazine (SSD) applied daily (n = 82)
Number of subjects: 153
Study 25909422 — intervention group
Group type: COMPARATOR
Intervention: Silver sulfadiazine (SSD)
Number of subjects: 153
Study 23371005 — intervention group
Group type: EXPERIMENTAL
Intervention: Provictim attitudes (defined as children's beliefs that bullying is unacceptable, victims are acceptable, and defending victims is valued)
Number of subjects: 16634
Study 23371005 — intervention group
Group type: EXPERIMENTAL
Intervention: Teachers' ability to intervene in bullying (assessed at the classroom level)
Number of subjects: 16634
Study 21288733 — intervention group
Group type: EXPERIMENTAL
Intervention: CoSeal® surgical sealant
Number of subjects: 121
Study 21288733 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 121
Study 19053983 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG/RBV
Number of subjects: 232
Study 17234675 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream (lidocaine 25 mg-prilocaine 25 mg/G) applied to the uterine cervix 30 min before HSG
Number of subjects: 82
Study 17234675 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream applied to the uterine cervix 30 min before HSG
Number of subjects: 82
Study 15612846 — intervention group
Group type: EXPERIMENTAL
Intervention: High improved symptom trajectory
Number of subjects: 156
Study 15612846 — intervention group
Group type: EXPERIMENTAL
Intervention: High unimproved symptom trajectory
Number of subjects: 156
Study 15612846 — intervention group
Group type: EXPERIMENTAL
Intervention: Borderline improved symptom trajectory
Number of subjects: 156
Study 15612846 — intervention group
Group type: EXPERIMENTAL
Intervention: Borderline unimproved symptom trajectory
Number of subjects: 156
Study 15612846 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclinical symptom trajectory
Number of subjects: 156
Study 11352442 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400mg alone
Number of subjects: 12
Study 11352442 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400mg with Al3+ (sucralfate) 190mg
Number of subjects: 12
Study 9404449 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexarelin 0.25 microgram/kg
Number of subjects: 6
Study 9404449 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexarelin 0.5 microgram/kg
Number of subjects: 6
Study 9404449 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexarelin 2.0 micrograms/kg
Number of subjects: 6
Study 9404449 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH 1.0 microgram/kg
Number of subjects: 6
Study 9404449 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine 120 mg
Number of subjects: 6
Study 9404449 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine + Hexarelin 0.25 microgram/kg
Number of subjects: 6
Study 9404449 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine + GHRH
Number of subjects: 6
Study 9404449 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexarelin 0.25 microgram/kg + GHRH
Number of subjects: 6
Study 9404449 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine + Hexarelin 0.5 microgram/kg
Number of subjects: 6
Study 9404449 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine + Hexarelin 2.0 micrograms/kg
Number of subjects: 6
Study 7855193 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol group A (0.62 g/kg) with withholding knowledge of results (KR)
Number of subjects: 24